Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice

#2750

Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.

Aim(s): Secondary TELEACE outcomes measured the effect of TE on progression-free survival (PFS), time to tumor progression (TTP), body weight, ECOG PS, CS symptoms and serotonin levels.

Materials and methods: Retrospective chart review of 200 patients who initiated TE (2017–2018) and had ≥2 radiological scans in the 12 months before and ≥1 scan after TE initiation. Kaplan-Meier analyses estimated median PFS (TE initiation to tumor progression or death) and TTP. Chi-square test evaluated changes in documented CS symptoms (improved vs same/worsened). Descriptive statistics summarized changes in body weight, ECOG PS, urinary 5-hydroxyindoleacetic acid (u5-HIAA) and 5-hydroxytryptamine (5-HT).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Metz D

Authors: Metz D, Liu E, Joish V, Huynh L, Cheng M,

Keywords: neuroendocrine tumor, carcinoid syndrome, telotristat ethyl, serotonin, tumor growth, progression-free survival,